

Important Notes 重要提示

- 1 Manulife Global Fund – Healthcare Fund (the "Fund") invests in equity securities of listed companies in health care and related industries globally, which may involve equity market, sector and geographical concentration, health care, volatility, political and regulatory risks.
- 2 The Fund intends to use financial derivative instruments ("FDIs") for investment, efficient portfolio management and/or hedging purposes. The use of FDIs exposes the Fund to additional risks, including volatility risk, management risk, market risk, credit risk and liquidity risk.
- 3 Investment involves risk. The Fund may expose its investors to capital loss. Investors should not base on this material alone to make investment decisions and should read the offering document for details, including the risk factors, charges and features of the Fund and its share classes.

- 1 宏利環球基金 – 康健護理基金（「本基金」）投資於全球康健護理及相關工業的上市公司的股票證券，可能涉及股票市場、行業及地域集中、康健護理、波動性、政治及規管風險。
- 2 本基金擬使用金融衍生工具作投資、有效管理投資組合及/或對沖目的。金融衍生工具的使用導致本基金承受額外風險，包括波動風險、管理風險、市場風險、信用風險及變現風險。
- 3 投資涉及風險。本基金的投資者或須承受資本虧損。投資者不應只單靠本資料而作出投資決定，而應仔細閱讀銷售文件，以獲取詳細資料，包括本基金及其股份類別之風險因素、收費及產品特點。

Fund prices may go down as well as up. Past performance information presented are not indicative of future performance. Investor has his/her own personal investment objectives, investment products may not be suitable for everyone.

基金價格可跌亦可升。過往業績數據並非未來業績的指標。投資者的目標各有不同，投資產品未必適合所有投資者。

This material has not been reviewed by the Securities and Futures Commission.

證券及期貨事務監察委員會並未有審閱此文件。

Issued by Manulife Investment Management (Hong Kong) Limited.

由宏利投資管理（香港）有限公司刊發。

Information as of 資料截至 2024/04/30

Investment Objective 投資目標

This Fund aims to provide medium to long-term capital growth for those who hold a long-term investment view and who are prepared to accept significant fluctuations in the value of their investments in order to achieve long-term returns. It is intended that the investments will be made on a diversified basis. The underlying investment portfolio will mainly consist of equity and equity related securities of companies in health care and related industries globally and which are listed on any stock exchange. This Fund may invest in companies which derive a significant portion of their earnings from medical and pharmaceutical products and services. The remaining assets of this Fund may include bonds and deposits. This Fund will invest at least 80% of its net assets in equity and equity related securities of health sciences companies. These companies will derive more than half of their revenues from health care-related business activities or commit more than half of their assets to these activities. Such equity and equity related securities include common stocks, preferred stocks and depositary receipts.

本基金旨在為持有長期投資觀點、為了達致長期回報而願意接受其投資價值相當大的波幅的風險的投資者提供中長期資本增長。本基金有意在多元化的基礎上作出投資。其基本投資組合將主要包括全球康健護理及相關工業的、在任何證券交易所上市的公司之股票及股票相關證券。本基金可投資於其收益的重大部分來自醫療及醫藥產品及服務的公司。本基金的其餘資產可包括債券及存款。本基金將其最少80%的淨資產投資於健康科學公司的股票及股票相關證券。該等公司過半收入來自與康健護理有關的業務活動，或者將其資產多半用於該等活動。該等股票及股票相關證券包括普通股、優先股及預託證券。

Fund Information 基金資料


| | | | |
|--|--|---------------------|--|
| Investment Manager 投資管理人 | Manulife Investment Management (US) LLC | | |
| Launch Date (YYYY/MM/DD) 發行日期 | 2008/06/27 | | |
| Launch Price (per share) 發行價格(每股) | USD 1.00 | | |
| Base Currency 基礎貨幣 | USD 美元 | | |
| Available Class(es) and their Bloomberg/ISIN Code 可選擇之類別及其彭博/ISIN編號 | Bloomberg Ticker 彭博編號 | ISIN Code ISIN編號 | |
| Class AA (USD) AA(美元)類別 | MGFHEAL | LU0357321016 | |
| Fund Size 基金規模 | USD 398.79 million 百萬 | | |
| Initial Charge 初次收費 | Up to 5.00% 最多達5.00% | | |
| Redemption Charge 贖回費 | Nil 不適用 | | |
| Switching Charge 轉換費 | Up to 1.00% 最多達1.00% | | |
| Management Fee* 管理費* | 1.50% per annum of the NAV of this fund 每年本基金資產淨值的 1.50% | | |
| Minimum Initial Investment 最低初次投資額 | USD 1,000 | | |
| Minimum Subsequent Investment 最低其後投資額 | USD 100 | | |
| Net Asset Value (NAV) Per Share 每股資產淨值 | USD 3.1768 (Class AA (USD) AA(美元)類別) | | |
| Benchmark** 基準指數** | MSCI World/Health Care NR USD Index MSCI 明晟世界/健康護理淨回報美元指數 | | |
| Standard Deviation (3 Years) 標準差(三年) | 12.33% | | |

Calendar Year Performance 年度表現

| | 2023 | 2022 | 2021 | 2020 | 2019 |
|----------------------------|-------|--------|--------|--------|--------|
| Class AA (USD) AA(美元)類別 | 4.33% | -3.57% | 20.70% | 7.06% | 17.87% |
| Benchmark 基準指數 | 3.76% | -5.41% | 19.80% | 13.52% | 23.24% |

Cumulative Performance 累積表現

| | YTD 年初至今 | 3 months 三個月 | 1 yr. 一年 | 3 yrs. 三年 | 5 yrs. 五年 | Since Launch 成立至今 |
|----------------------------|-------------|-----------------|-------------|--------------|--------------|----------------------|
| Class AA (USD) AA(美元)類別 | 4.56% | 0.72% | 8.87% | 21.67% | 52.27% | 217.68% |
| Benchmark 基準指數 | 3.22% | 0.52% | 5.17% | 16.06% | 61.17% | 398.29% |

5-Year Cumulative Performance 五年累積表現

Top Holdings 主要持有成份

| | |
|---------------------------------|-------|
| Eli Lilly and Company | 9.73% |
| Novo Nordisk A/S Class B | 8.04% |
| Merck & Co., Inc. | 6.38% |
| AstraZeneca PLC | 5.14% |
| UnitedHealth Group Incorporated | 5.00% |
| Stryker Corporation | 4.33% |
| McKesson Corporation | 4.29% |
| Thermo Fisher Scientific Inc. | 3.73% |
| Abbott Laboratories | 3.71% |
| Johnson & Johnson | 3.15% |

**Geographical Breakdown~
地區分佈~**

| | |
|--------------------------------------|--------|
| United States 美國 | 72.82% |
| Denmark 丹麥 | 9.44% |
| United Kingdom 英國 | 7.17% |
| Japan 日本 | 3.09% |
| Switzerland 瑞士 | 2.66% |
| Belgium 比利時 | 0.87% |
| Germany 德國 | 0.65% |
| China 中國 | 0.40% |
| Spain 西班牙 | 0.10% |
| Cash & Cash Equivalents 現金及現金等值資產 | 2.79% |

**Sector Breakdown~
類別分佈~**

| | |
|---|--------|
| Pharmaceuticals 製藥 | 41.64% |
| Healthcare Equipment & Supplies 醫療保健設備與用品 | 18.40% |
| Healthcare Providers & Services 醫療保健供應商與服務 | 15.42% |
| Biotechnology 生物技術 | 12.96% |
| Life Sciences Tools & Services 生命科學工具與服務 | 8.68% |
| Health Care Technology 醫療保健科技 | 0.11% |
| Cash & Cash Equivalents 現金及現金等值資產 | 2.79% |

Source: Manulife Investment Management (US) LLC and Manulife Investment Management (Hong Kong) Limited unless otherwise indicated. All the performance figures are on NAV to NAV basis, in base currency with dividends reinvested. The sourced information contained herein is not warranted to be accurate, complete or timely. Neither Manulife Investment Management (Hong Kong) Limited nor any of its affiliates are responsible for any damages or losses arising from any use of this information. 資料來源：Manulife Investment Management (US) LLC及宏利投資管理(香港)有限公司或另有說明。所有的業績數據以資產淨值對資產淨值及基礎貨幣計算，股息再投資。本文件內所提供的資料並未就其準確性、完整性、及時間性作出保證。宏利投資管理(香港)有限公司及其任何聯繫公司均不負責任何因使用該等資料而引致的損害及損失。

With effect as from 30 June 2021, the annual management fee reduced from 1.75% to 1.50%. Annual Management Fee may be increased to a maximum of 6% of the Net Asset Value of the relevant Fund by giving not less than three months' prior notice of the proposed increase to the Depository and to the Shareholders of the relevant Fund. Please refer to the Fund prospectus for details. 自2021年6月30日起生效，每年管理費由1.75%下調至1.50%。管理費可增加至最高為有關基金的資產淨值的6%，但須就擬作出的增加給予存管處及有關基金的股東至少三個月的事先通知。詳情請參閱本基金的基金章程。

** The benchmark was changed from Russell 3000 Healthcare Index to the current one in January 2013. 於2013年1月，基準指數由羅素3000康健護理指數更改至現時之指數。

~ Due to rounding, the total may not be equal to 100%. A negative percentage, if any, represents a short position in the portfolio for hedging/cash flow management purposes. Please refer to offering document of the Fund for details. 數字經修整後，總計可能並不相等於100%。負數百分比(如有)代表投資組合為了對沖或現金流管理而持有短倉。有關詳情請參閱本基金之銷售文件。

This fund invests in a single sector, which may involve concentration, volatility, political and regulatory risks. Investors may potentially expose to capital loss. 本基金投資於單一行業，可能涉及集中性、波動性、政治及規管風險。投資者或須承受資本虧損。